Deuruxolitinib (CTP-543) is a Janus kinase inhibitor selective for JAK1 and JAK2. It is in development to treat alopecia areata.[1] If approved the drug would compete with others with a similar mechanism of action developed by Eli Lilly and Pfizer.[2]
Deuruxolitinib is a deuterated derivative of ruxolitinib.
^King, Brett; Mesinkovska, Natasha; Mirmirani, Paradi; Bruce, Suzanne; Kempers, Steve; Guttman-Yassky, Emma; Roberts, Janet L.; McMichael, Amy; Colavincenzo, Maria; Hamilton, Colleen; Braman, Virginia; Cassella, James V. (August 2022). "Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata". Journal of the American Academy of Dermatology. 87 (2): 306–313. doi:10.1016/j.jaad.2022.03.045. ISSN 1097-6787. PMID 35364216. S2CID 247866262.
^Taylor, Nick Paul (2022-05-23). "Chasing Lilly and Pfizer, Concert's JAK inhibitor hits high notes in phase 3 alopecia trial". Fierce Biotech. Retrieved 2023-11-11.
Deuruxolitinib (CTP-543) is a Janus kinase inhibitor selective for JAK1 and JAK2. It is in development to treat alopecia areata. If approved the drug would...
The molecular formula C17H18N6 may refer to: Deuruxolitinib Ruxolitinib This set index page lists chemical structure articles associated with the same...